Hidradenitis suppurativa (HS) is an important inflammatory disease, which affects approximately 1% of adults, and causes painful nodules, draining abscesses, and disfiguring scars that make walking, sitting, and working difficult or impossible. Progress to investigate HS is impeded by the lack of comprehensive outcome measures for use in trials and clinical care. Existing HS-specific disease severity tools are limited because signs of disease damage, such as discoloration and scarring, are either not captured or incorporated into a single score. In addition, some tools are impractical or not validated, reliable, or responsive. A disease-specific patient-reported outcome measure does not exist and given the impact of HS on patient well-being, it is vital to engage patients in outcome measurement. The goal of this proposal is to develop HS-specific measures to support accurate disease assessment.
The specific aims of the proposed research are: (1) to test the hypothesis that a novel HS-specific patient-reported outcome measure will have substantial validity, reliability and responsiveness; (2) to test the hypothesis that a new provider-reported disease severity measure will have substantial validity, reliability and responsiveness. Patients with HS, age 18 or older, will be recruited from the PaTH network, an integrated clinical data research network across four Mid-Atlantic health systems, Penn State Hershey Medical Center, University of Pittsburgh Medical Center, Johns Hopkins Medical Center, and Temple Health System. The patients in the PaTH network are diverse; over 25% are non-white; 20% have public insurance or no insurance. The development and validation process will be based on the NIH PROMIS Instrument Development and Validation Scientific Standards. Briefly, we will include stakeholders, patients and providers, in the development and refinement of the tools. We will rigorously test the psychometric and measurement properties, including the reliability and validity, with the input of patients and providers. Finally, we will focus on evaluating the responsiveness of these novel patient- and clinician-reported outcome measures for HS.

Public Health Relevance

Hidradenitis suppurativa (HS) is a common but not well-understood inflammatory disease that causes painful swollen nodules, draining abscesses, and disfiguring scars of the skin folds. People with HS have an increased risk of metabolic syndrome, diabetes, depression, and anxiety. Progress to investigate HS is impeded by the lack of validated, comprehensive outcome measures. This project will develop two reliable, validated patient- and provider-reported outcome measures for HS.

National Institute of Health (NIH)
Agency for Healthcare Research and Quality (AHRQ)
Clinical Investigator Award (CIA) (K08)
Project #
Application #
Study Section
HSR Health Care Research Training SS (HCRT)
Program Officer
Willis, Tamara
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Pennsylvania State University
Schools of Medicine
United States
Zip Code
Thorlacius, L; Garg, A; Ingram, J R et al. (2018) Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. Br J Dermatol 178:715-721
Thorlacius, L; Ingram, J R; Villumsen, B et al. (2018) A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. Br J Dermatol 179:642-650
Sisic, Mia; Kirby, Joslyn S; Boyal, Sanwarjit et al. (2017) Development of a Quality-of-Life Measure for Hidradenitis Suppurativa. J Cutan Med Surg 21:152-155
Thorlacius, Linnea; Ingram, John R; Garg, Amit et al. (2017) Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. BMJ Open 7:e014733
Kirby, Joslyn S; Sisic, Mia; Tan, Jerry (2016) Exploring Coping Strategies for Patients With Hidradenitis Suppurativa. JAMA Dermatol 152:1166-1167
Kirby, Joslyn S (2016) Qualitative study shows disease damage matters to patients with hidradenitis suppurativa. J Am Acad Dermatol 74:1269-70